The Rise of GLP-1 Molecules

Explore the future of obesity treatment and the talent powering it

This in-depth ARTO whitepaper unpacks the seismic shift happening in obesity care through GLP-1 therapies. With the market forecast to exceed $100 billion by 2030, the report examines the scientific breakthroughs, soaring investor confidence, and global talent race driving rapid progress in this space.

Key insights include:

• Market momentum: Obesity rates are climbing, but so is innovation. Semaglutide-based drugs like Ozempic and Wegovy are reshaping treatment expectations.

• Investment surge: Big pharma and venture capital are backing obesity R&D like never before, with major acquisitions and manufacturing expansion already underway.

• Regulatory breakthroughs: FDA and EMA approvals are accelerating, and new dual- and triple-agonist therapies are pushing weight loss results further.

• Talent challenges: From AI-powered R&D to global CRO partnerships, companies are navigating a fierce war for talent.

• Workforce trends: Shortages of metabolic experts and rising salary expectations are changing how firms recruit and retain top minds across Europe, Asia, and North America.

For life sciences leaders, this report is your strategic overview of where the science, the market, and the people are heading next.

Download the whitepaper to stay ahead in one of the fastest-moving spaces in healthcare.